|
|
|
| Study on the reversal effect and mechanism of tetrandrine for Cisplatin-resistant breast cancer cells based on ATP7A |
| XIAO Yi MA Dachang WANG Honglei JI Kun WU Li |
| Department of Breast Surgery, the First Hospital of Lanzhou University, Gansu Province, Lanzhou 730000, China |
|
|
|
Abstract Objective To explore the reversal effect and mechanism of tetrandrine for Cisplatin-resistant breast cancer cells based on ATP7A. Methods Two kinds of human Cisplatin-resistant breast cancer cells lines and cells with high expression of ATP7A were established to detect the reversal effects of tetrandrine on Cisplatin-resistant breast cancer cells. The intracellular content of Cisplatin was determined by high performance liquid chromatography and the expression of ATP7A protein was detected. Results The sensitivity of Cisplatin in resistant breast cancer cells was significantly decreased (P ＜ 0.05), the expression of ATP7A protein was increased (P ＜ 0.05), and the intracellular content of Cisplatin was decreased significantly (P ＜ 0.05); compared with normal breast cancer cells, the sensitivity of Cisplatin in cells with high expression of ATP7A significantly decreased (P ＜ 0.05), and the intracellular content of Cisplatin was decreased significantly (P ＜ 0.05). Tetrandrine had significant reversal effects for the drug resistance of cells, which could increase the intracellular content of Cisplatin (P ＜ 0.05), and decrease the expression of ATP7A compared with drug-resistant cells and transfected cells (P ＜ 0.05). Conclusion Tetrandrine has reversal effects for human Cisplatin-resistant breast cancer cells lines and cells with high expression of ATP7A, its mechanism may be related to the inhibition of ATP7A expression.
|
|
|
|
|
|
[1] Mandala M，Tondini C. Adjuvant therapy in breast cancer and venous thromboembolism [J]. Thromb Res，2012，130（1）：66-70.
[2] Li ZF，Wang SM，Shi JF，et al. Combined screening of cervical cancer，breast cancer and reproductive tract infections in rural China [J]. Asian Pac J Cancer Prev，2012，13（7）：3529-3533.
[3] Galluzzi L，Vitale I，Michels J，et al. Systems biology of cisplatin resistance：past，present and future [J]. Cell Death Dis，2014，5：e1257.
[4] Arslan C，Ozdemir E，Altundag K，et al. Secondary hematological malignancies after treatment of non-metastatic breast cancer [J]. J Buon，2011，16（4）：744-750.
[5] 刘嘉琪，张雅男，赵婉，等.粉防己化学成分及药理学研究进展[J].中医药学报，2017，45（3）：100-103.
[6] 韩彬，王国俊，罗恒丽.粉防己碱药理作用研究进展[J].临床合理用药，2014，7（3）：198-199.
[7] 闫冠韫，王立波，程伟.中药抗肿瘤生物碱类药物的研究进展[J].中医药学报，2013，41（2）：101-103.
[8] 陈晓松，包明红，梅晓冬.粉防己碱对人口腔上皮癌多药耐药KB-MRP1细胞株多药耐药性的逆转作用[J].癌症，2007，26（8）：846-850.
[9] 李海燕，陈阳，何琪杨.苦参碱与粉防己碱逆转人MCF-7 细胞耐药性的作用与机制[J].中国实验方剂学杂志，2013，19（18）：275-278.
[10] 盛佳钰，时百玲，陈红风.三阴性乳腺癌MDA-MB-231顺铂耐药细胞株的建立及鉴定[J].肿瘤防治研究，2016， 43（3）：175-180.
[11] 周琼，郁韵秋.高效液相色谱法测定乳剂中顺铂含量[J].中国医院药学杂志，1999，19（2）：78-80.
[12] Weiss RB，Christian MC. New cisplatin analogues in development. A review [J]. Drugs，1993，46（3）：360-377
[13] 朱星枚，吴琳，张媛，等.细胞自噬与人卵巢癌细胞对顺铂耐药的关系[J].中国医药导报，2016，13（25）：12-16.
[14] Jakupec MA，Galanski M，Keppler BK. Tumour-inhibiting platinum complexes-state of the art and future perspectives [J]. Rev Physiol Biochem Pharmacol，2003，146（6）：1-53.
[15] Natile G，Coluccia M. Current status of trans-platinum compounds in cancer therapy [J]. Coordination Chemistry Reviews，2001，216（6）：383-410.
[16] Zhang Y，LiM，Yao Q，et al. Roles and mechanisms of coppertran sporting ATPases in cancer pathogenesis [J]. Med Sci Monit，2009，15（1）：RA1-RA5.
[17] Leonhardt K，Gebhardt R，M?觟ssner J，et al. Functional Interactions of Cu-ATPase ATP7B with Cisplatin and the Role of ATP7B in the Resistance of Cells to the Drug [J]. J Biol Chem，2009，284（12）：7793-7802.
[18] Kuo MT，Chen HH，Song IS，et al. The roles of copper transporters in cisplatin resistance [J]. Cancer Metastasis Rev，2007，26（1）：71-83.
[19] 邢志博，王凤梅，王翠平，等.粉防己有效成分的药理活性研究进展[J].中国实验方剂学杂志，2014，20（9）：241-246.
[20] He QY，Meng FH，Zhang HQ. Reduction of doxorubicin resistance by tet randrine and dauricine in harringtonine-resistant human leukemia（HL60）cells [J]. Acta Pharmacologica Sinica，1996，7（2）：179-181. |
|
|
|
